About VIEWPOINT MOLECULAR TARGETING, INC.
Perspective Therapeutics is a radiopharmaceutical company dedicated to developing image-guided, targeted alpha-particle therapies (TATs) for the treatment of cancer. The company focuses on innovative therapies using Pb-212-based alpha-particle radiotherapies to deliver powerful radiation directly to cancer cells.
Development of image-guided, targeted alpha-particle therapies (TATs) for cancer treatmentUtilization of Pb-212-based alpha-particle radiotherapies with high-affinity targeting peptidesImage-guided theranostics platform for tumor imaging and treatment optimizationProprietary Pb-specific chelator technology for tumor imaging and radiopharmaceutical delivery
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to VIEWPOINT MOLECULAR TARGETING, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.